FGFR3
Bladder cancer
Phase 1/2Active
Key Facts
About Onco3R Therapeutics
Onco3R Therapeutics is a Belgian clinical-stage biotech developing precision medicines for oncology and immunology with a portfolio of five disclosed programs. The company leverages a seasoned team with over 150 years of combined R&D experience and a dual-modality approach, utilizing both small molecules and antibodies to target clinically validated pathways. Its strategy focuses on designing best-in-class therapies by learning from the liabilities of first-generation drugs to improve safety and efficacy.
View full company profileTherapeutic Areas
Other Bladder cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Measovir®-based candidate | Oncovita | Pre-clinical |
| ADC Resistance in Bladder Cancer | Elucidate Bio | Research |
| Platin-DRP® | Chosa Oncology | Development |
| PanGIA Bladder | PanGIA Biotech | Pre-clinical |
| Intravesical IL-2 | Immunservice | Pre-clinical |
| Urine-based Bladder Cancer Detection | Qurin Diagnostics | Pre-clinical |